Next, we evaluated the expression signature of TRM-like cells to predict the response to anti-PD-1 immunotherapy using bulk RNA-seq data and clinical information available for two independent public cohorts of patients with NSCLC (GSE126045 and GSE135222)60,61. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.